FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases
The agency's new "Plausible Mechanism Framework" creates a first-of-its-kind regulatory pathway for genome editing and RNA-based therapies targeting small patient populations where traditional clinical trials are not feasible. The U.S.…